253 related articles for article (PubMed ID: 35508333)
1. Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell.
Girkin JLN; Maltby S; Bartlett NW
Eur Respir Rev; 2022 Jun; 31(164):. PubMed ID: 35508333
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.
Proud PC; Tsitoura D; Watson RJ; Chua BY; Aram MJ; Bewley KR; Cavell BE; Cobb R; Dowall S; Fotheringham SA; Ho CMK; Lucas V; Ngabo D; Rayner E; Ryan KA; Slack GS; Thomas S; Wand NI; Yeates P; Demaison C; Zeng W; Holmes I; Jackson DC; Bartlett NW; Mercuri F; Carroll MW
EBioMedicine; 2021 Jan; 63():103153. PubMed ID: 33279857
[TBL] [Abstract][Full Text] [Related]
3. Innate and Adaptive Immune Responses in the Upper Respiratory Tract and the Infectivity of SARS-CoV-2.
Ramasamy R
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632675
[TBL] [Abstract][Full Text] [Related]
4. An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants.
Kayesh MEH; Kohara M; Tsukiyama-Kohara K
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835108
[TBL] [Abstract][Full Text] [Related]
5. TLRs: Innate Immune Sentries against SARS-CoV-2 Infection.
Mantovani S; Oliviero B; Varchetta S; Renieri A; Mondelli MU
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175768
[TBL] [Abstract][Full Text] [Related]
6. Case report: hepatitis in a child infected with SARS-CoV-2 presenting toll-like receptor 7 Gln11Leu single nucleotide polymorphism.
Pessoa NL; Bentes AA; de Carvalho AL; de Souza Silva TB; Alves PA; de Sousa Reis EV; Rodrigues TA; Kroon EG; Campos MA
Virol J; 2021 Sep; 18(1):180. PubMed ID: 34482844
[TBL] [Abstract][Full Text] [Related]
7. Perspective of the Relationship between the Susceptibility to Initial SARS-CoV-2 Infectivity and Optimal Nasal Conditioning of Inhaled Air.
Ramasamy R
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360686
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
9. The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives.
Boechat JL; Chora I; Morais A; Delgado L
Pulmonology; 2021; 27(5):423-437. PubMed ID: 33867315
[TBL] [Abstract][Full Text] [Related]
10. CCR2 Signaling Restricts SARS-CoV-2 Infection.
Vanderheiden A; Thomas J; Soung AL; Davis-Gardner ME; Floyd K; Jin F; Cowan DA; Pellegrini K; Shi PY; Grakoui A; Klein RS; Bosinger SE; Kohlmeier JE; Menachery VD; Suthar MS
mBio; 2021 Dec; 12(6):e0274921. PubMed ID: 34749524
[TBL] [Abstract][Full Text] [Related]
11. Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques.
White AD; Sibley L; Sarfas C; Morrison AL; Bewley K; Churchward C; Fotheringham S; Gkolfinos K; Gooch K; Handley A; Humphries HE; Hunter L; Kennard C; Longet S; Mabbutt A; Moffatt M; Rayner E; Tipton T; Watson R; Hall Y; Bodman-Smith M; Gleeson F; Dennis M; Salguero FJ; Carroll M; McShane H; Cookson W; Hopkin J; Sharpe S
Front Immunol; 2021; 12():801799. PubMed ID: 35222355
[TBL] [Abstract][Full Text] [Related]
12. Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities.
Galani IE; Andreakos E
Semin Immunol; 2021 Jun; 55():101522. PubMed ID: 34815163
[TBL] [Abstract][Full Text] [Related]
13. The molecular mechanism of SARS-CoV-2 evading host antiviral innate immunity.
Gu W; Gan H; Ma Y; Xu L; Cheng ZJ; Li B; Zhang X; Jiang W; Sun J; Sun B; Hao C
Virol J; 2022 Mar; 19(1):49. PubMed ID: 35305698
[TBL] [Abstract][Full Text] [Related]
14. Roles of RNA Sensors in Host Innate Response to Influenza Virus and Coronavirus Infections.
Li W; Wang H; Zheng SJ
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955436
[TBL] [Abstract][Full Text] [Related]
15. Toll-like Receptor Mediation in SARS-CoV-2: A Therapeutic Approach.
Manan A; Pirzada RH; Haseeb M; Choi S
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142620
[TBL] [Abstract][Full Text] [Related]
16. Antiviral innate immunity is diminished in the upper respiratory tract of severe COVID-19 patients.
Ramos-Benitez MJ; Strich JR; Alehashemi S; Stein S; Rastegar A; de Jesus AA; Bhuyan F; Ramelli S; Babyak A; Perez-Valencia L; Vannella KM; Grubbs G; Khurana S; Gross R; Hadley K; Liang J; Mazur S; Postnikova E; Warner S; Holbrook MR; Busch LM; Warner B; Applefeld W; Warner S; Kadri SS; Davey RT; Goldbach-Mansky R; Chertow DS
medRxiv; 2022 Nov; ():. PubMed ID: 36415460
[TBL] [Abstract][Full Text] [Related]
17. Co-infection of SARS-CoV-2 with other respiratory viruses and performance of lower respiratory tract samples for the diagnosis of COVID-19.
Burrel S; Hausfater P; Dres M; Pourcher V; Luyt CE; Teyssou E; Soulié C; Calvez V; Marcelin AG; Boutolleau D
Int J Infect Dis; 2021 Jan; 102():10-13. PubMed ID: 33115679
[TBL] [Abstract][Full Text] [Related]
18. Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D.
Peng MY; Liu WC; Zheng JQ; Lu CL; Hou YC; Zheng CM; Song JY; Lu KC; Chao YC
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065735
[TBL] [Abstract][Full Text] [Related]
19. Host Recovery from Respiratory Viral Infection.
Wei X; Narasimhan H; Zhu B; Sun J
Annu Rev Immunol; 2023 Apr; 41():277-300. PubMed ID: 36716750
[TBL] [Abstract][Full Text] [Related]
20. The Immunopathobiology of SARS-CoV-2 Infection.
Patel M; Shahjin F; Cohen JD; Hasan M; Machhi J; Chugh H; Singh S; Das S; Kulkarni TA; Herskovitz J; Meigs DD; Chandra R; Hettie KS; Mosley RL; Kevadiya BD; Gendelman HE
FEMS Microbiol Rev; 2021 Nov; 45(6):. PubMed ID: 34160586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
